Social Media Use During COVID-19

July 4, 2020 updated by: Jean Liu

Getting it Right: Towards Responsible Social Media Use During a Pandemic

The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1145

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Singapore
      • Singapore, Singapore, 138527
        • Yale-NUS College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Representative sample of the Singapore population

Description

Inclusion Criteria:

  • At least 21 years
  • Has stayed in Singapore for at least 2 years

Exclusion Criteria:

  • Below 21 years
  • Has stayed in Singapore for less than 2 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Community sample
We plan to recruit a representative sample of the Singapore population.
Behavioral: Use of social media during COVID-19
Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
Other Names:
  • WhatsApp

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression, Anxiety and Stress Scale
Time Frame: Single measurement (upon study enrolment)
21-item validated scale assessing symptoms of depression, anxiety, and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome
Single measurement (upon study enrolment)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of COVID-19 situation
Time Frame: Single measurement (upon study enrolment)
3 items on fear of the situation, confidence the government can manage the situation, and assessed chance of being infected (each rated using 4-point scales: min = 1, max = 4; higher scores indicate increased confidence / likelihood / fear)
Single measurement (upon study enrolment)
Familiarity and trust in COVID-related rumours
Time Frame: Single measurement (upon study enrolment)
Participants' self-report of their familiarity (yes/no) and belief of specific (yes/no), and whether they shared these on social media (yes/no)
Single measurement (upon study enrolment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jean Liu

Investigators

  • Principal Investigator: Jean Liu, PhD, Yale-NUS College

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2020

Primary Completion (Actual)

April 21, 2020

Study Completion (Actual)

April 21, 2020

Study Registration Dates

First Submitted

March 8, 2020

First Submitted That Met QC Criteria

March 11, 2020

First Posted (Actual)

March 12, 2020

Study Record Updates

Last Update Posted (Actual)

July 7, 2020

Last Update Submitted That Met QC Criteria

July 4, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-CERC-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to stipulations by the Institutional Review Board, data cannot be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Use of social media during COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe